Mesa Laboratories, Inc

In 2024, Gary Owens, the CEO and President of Mesa Laboratories, led the company with a total compensation package of $5,435,566. This amount included a base salary of $754,000, stock awards valued at $3,560,850, option awards of $774,002, other forms of compensation totaling $15,114, and $331,600 under incentive plan-based compensation. Notably, Owens did not receive any bonus, indicating a compensation structure heavily reliant on stock and incentives, aligning well with shareholder interests by potentially driving long-term stock performance.^1


Looking back at 2023, Greg DiNoia, who served as the former Senior Vice President of Commercial, received a total compensation of $1,106,238. This included a relatively modest salary of $105,011, along with stock awards worth $101,692, options valued at $164,602, and a substantial figure of $734,932 under "all other compensation." This package did not feature any incentive-based compensation or bonuses, highlighting a different emphasis in his compensation package than Owens', potentially focusing on different strategic needs of the company at that time.^2

In comparison, the 2022 compensation of Brian Archbold, the Senior Vice President of Operations and Continuous Improvement, amounted to $1,200,506. His package was dominated by a $297,018 salary, $430,549 in stock awards, and $260,064 in option awards. Archbold also received $200,680 through incentive plans, indicating a balanced approach between immediate salary and long-term incentives aligning with operational goals and efficiency improvements.^3

Additionally, Greg DiNoia’s compensation in 2020, when he served as the Senior Vice President of Commercial Operations, was $898,969. This compensation consisted of a salary of $341,285, $204,828 in stock awards, and $202,983 in option awards, supplemented by $144,328 in incentive plan compensation and $5,545 in other compensation. This structured mix reflects the compensation strategies pre-and during the early COVID-19 period, focusing on stability and alignment with changing market conditions.^4^5

These shifts in compensation underscore a strategic emphasis on stock awards and long-term incentives at Mesa Laboratories, likely aimed at aligning executive interests with shareholder value, especially during turbulent economic times. The company's strong performance, with a current stock price of $133.26, increasing 4.46% from the previous trading day, reflects positively on these decisions. The firm's stock reached a year-high of $141.17, and with a market capitalization of approximately $723.79 million, shares outstanding number 5,431,420. These financial indicators suggest Mesa Laboratories is strategically navigating its financial landscape with proficient executive leadership.^6

---
^1 "Gary Owens CEO and President Compensation." SEC Filing, 2024. [Link](https://www.sec.gov/Archives/edgar/data/724004/000143774924023040/0001437749-24-023040-index.htm).

^2 "Greg DiNoia Former SVP Commercial Compensation." SEC Filing, 2023. [Link](https://www.sec.gov/Archives/edgar/data/724004/000143774923019920/0001437749-23-019920-index.htm).

^3 "Brian Archbold SVP of Operations and Continuous Improvement Compensation." SEC Filing, 2022. [Link](https://www.sec.gov/Archives/edgar/data/724004/000143774922017099/0001437749-22-017099-index.htm).

^4 "Greg DiNoia SVP of Commercial Operations Compensation, 2020." SEC Filing. [Link](https://www.sec.gov/Archives/edgar/data/724004/000143774921017028/0001437749-21-017028-index.htm).

^5 "Greg DiNoia SVP of Commercial Operations Compensation, 2020." SEC Filing. [Link](https://www.sec.gov/Archives/edgar/data/724004/000143774920015316/0001437749-20-015316-index.htm).

^6 "Mesa Laboratories, Inc. Current Price Snapshot." Market Data, 2024.